No benefit from pazopanib in advanced kidney cancer after surgery to remove metastases Medical Xpress
Now open: Nominations for the 2020 Young Investigator Award More Here
Don’t miss the Q4 2019 Advocacy Newsletter More Here
Accepting ComboMATCH concept sheets until further notice More Here
Komal Jhaveri, MD, FACP (Memorial Sloan Kettering) is the primary author on the publication of NCI-MATCH Arm Q results, published in the Annals of Oncology. The antibody-drug conjugate ado-trastuzumab emtansine (T-DM1) has promising activity in HER2 amplified salivary gland tumors. More Here
Vitaly Margulis, MD (U Texas Southwestern) and colleagues report on the phase two study EA8141. The results support the use of four cycles of chemotherapy consisting of methotrexate, vinblastine, doxorubicin, and cisplatin (aMVAC) prior to surgery in patients with high-grade upper urinary tract cancer, a rare but treatable disease. The Journal of Urology
Bapsi Chakravarthy, MD (Vanderbilt) and colleagues report final results from study E5204. This phase three trial tested whether the addition of bevacizumab to mFOLFOX6, following neoadjuvant chemoradiation and definitive surgery, could improve overall survival in patients with stage II/III adenocarcinoma of the rectum. At 17% of its planned accrual, E5204 did not meet its primary endpoint. Published results inform the use of adjuvant therapy following neoadjuvant therapy. The Oncologist
The Journal of Clinical Oncology reports results for Arm Z1D of NCI-MATCH. “The confirmed overall response rate for nivolumab in tumors with DNA mismatch repair deficiencies was 36%–or 15 of 42 patients with cancers other than colon,” says Nilofer Azad, MD (Johns Hopkins) More Here
“Having insurance in and of itself was not enough to ensure access to a clinical trial or a good clinical outcome,” says Samilia Obeng-Gyasi, MD (The Ohio State University) on breast cancer patients with government insurance being at higher risk of death than privately insured More Here
E1912: Tait Shanafelt, MD (Stanford University) and colleagues report extended follow-up data for this practice-changing chronic lymphoctyic leukemia (CLL) trial at the 61st American Society of Hematology Annual Meeting More Here
PrECOG and Oncolytics Biotech® announce their collaboration for the BRACELET-1 (PrE0113) study to evaluate pelareorep in patients with metastatic breast cancer More Here
San Antonio Breast Cancer Symposium honors ECOG-ACRIN vice chair Joseph A. Sparano, MD with its prestigious William L. McGuire Memorial Lecture Award More Here
Results from E1305, a randomized phase III trial, are published in the Journal of Clinical Oncology online ahead of print, on October 16, 2019. The addition of bevacizumab to chemotherapy did not improve overall survival in squamous cell carcinoma of the head and neck, but improved the response rate and progression-free survival with increased toxicities. These results encourage biomarker-driven studies of angiogenesis inhibitors with better toxicity profiles in select patients. More Here
Visit the Press Center
TAILORx: New data are published September 30, 2019 in JAMA Oncology and orally presented at the European Society for Medical Oncology (ESMO) 2019 Congress. This is the fourth peer-reviewed publication for TAILORx, which continues to define new standards in early breast cancer. More Here
The results of leukemia trial E1912 are published in the New England Journal of Medicine. Tait Shanafelt, MD (Stanford University) and colleagues report that treatment with the combination of ibrutinib and rituximab is superior to standard treatment for patients 70 years of age or younger, with chronic lymphocytic leukemia (CLL) More Here
The Journal of Clinical Oncology has published the results of the ACRIN 6685 trial. Val J. Lowe, MD (Mayo Clinic) and colleagues report that surgical planning for head and neck cancer benefits from FDG-PET/CT, especially in patients who are clinically node-negative More Here
View the following video highlights on our YouTube channel:
Welcome to the ECOG-ACRIN Cancer Research Group website, the source of information about the cooperative group that was formed by the merger of the Eastern Cooperative Oncology Group (ECOG) and the American College of Radiology Imaging Network (ACRIN). We are excited to share news of our collaborative effort to design and conduct ground-breaking translational and clinical research.
The merger brought together the strengths and capabilities of two highly respected organizations. Since 1955, ECOG has performed practice-changing multicenter cancer clinical trials, working with more than 6000 physicians, nurses, pharmacists, statisticians, clinical research associates, and cancer research advocates from the United States and around the world. ACRIN, the premier imaging science program in the nation, complements ECOG’s research efforts with its expertise in early detection, imaging diagnosis, comparative-effectiveness research, and cost-effectiveness analysis. Now, as a single entity, we aim to achieve earlier cancer detection, more successful therapeutic intervention, higher rates of prevention, and better patient outcomes.
We look forward to sharing our research and partnering with you, as we reshape the future of patient care.
Robert L. Comis, MD